| Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers M Panagopoulou, M Karaglani, I Balgkouranidou, E Biziota, T Koukaki, ... Oncogene 38 (18), 3387-3401, 2019 | 138 | 2019 |
| Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients EI Karamitrousis, I Balgkouranidou, N Xenidis, K Amarantidis, E Biziota, ... Technology in cancer research & treatment 20, 1533033820973279, 2021 | 17 | 2021 |
| Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity C Ioannou, G Ragia, I Balgkouranidou, N Xenidis, K Amarantidis, ... Pharmacogenomics 22 (11), 669-680, 2021 | 9 | 2021 |
| MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements C Ioannou, G Ragia, I Balgkouranidou, N Xenidis, K Amarantidis, ... Drug Metabolism and Personalized Therapy 37 (3), 323-327, 2022 | 6 | 2022 |
| Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer E Karamitrousis, I Balgkouranidou, N Xenidis, K Amarantidis, E Biziota, ... Clinical Chemistry and Laboratory Medicine (CCLM) 59 (2), e73-e75, 2021 | 4 | 2021 |
| Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece G Ragia, A Maslarinou, N Atzemian, E Biziota, T Koukaki, C Ioannou, ... Frontiers in Pharmacology 14, 1248898, 2023 | 3 | 2023 |
| Assesment of SOX-17 gene promoter hypermethylation in hepatocellular carcinoma. L Chelis, I Balgouranidou, T Koukaki, P Michailidis, E Christakidis, ... Journal of Clinical Oncology 31 (15_suppl), e15063-e15063, 2013 | 3 | 2013 |
| Circulating biomarkers of sorafenib efficacy in advanced HCC. L Chelis, K Anagnostopoulos, G Trypsianis, EK Hamalidou, N Xenidis, ... Journal of Clinical Oncology 31 (4_suppl), 302-302, 2013 | 2 | 2013 |
| Concentration of circulating tumour DNA in patients with metastatic gastric cancer and its prognostic significance E Karamitrousis, I Balgkouranidou, N Xenidis, K Amarantidis, E Biziota, ... Forum of Clinical Oncology 12 (3), 72-76, 2021 | 1 | 2021 |
| Prognostic significance of BRCA1 and BRCA2 methylation status in circulating cell-free DNA of Pancreatic Cancer patients T Koukaki, I Balgkouranidou, E Biziota, A Karayiannakis, H Bolanaki, ... Journal of Cancer 15 (9), 2573, 2024 | | 2024 |
| MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations G Ragia, E Biziota, T Koukaki, K Amarantidis, VG Manolopoulos Pharmacogenomics, 2024 | | 2024 |
| Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, ... Hippokratia 27 (1), 7, 2023 | | 2023 |
| Adjuvant radiotherapy induces secondary tumor events in breast cancer patients with Li-Fraumeni syndrome K Rounis, T Koukaki, C Christodoulou, C Papadimitriou, D Tryfonopoulos, ... Annals of Oncology 30, iii30, 2019 | | 2019 |
| Methylation status of RASSF1A associates with prognosis in metastatic gastric cancer E Karamitrousis, I Balgkouranidou, N Xenidis Gastroenterol Hepatol Open Access 10 (6), 301-304, 2019 | | 2019 |
| The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC). L Chelis, N Xenidis, K Amarantidis, N Diamantopoulos, AL Boutis, ... Journal of Clinical Oncology 32 (3_suppl), 617-617, 2014 | | 2014 |
| in cancer: gender-dependent effect on dose requirements C Ioannou, G Ragia, I Balgkouranidou, N Xenidis, K Amarantidis, ... | | |
Kyriakos AmarantidisVerified email at pgna.gr
